Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2189102 · 2 trials · 2 indications
Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). The Least Squares (LS) Mean Value was based on an analysis of covariance (ANCOVA) model with treatment and site as class variables and baseline HbA1c as a continuous covariate.
Clinically significant events were defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of s SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| 0.6 milligrams (mg) LY2189102 | EXPERIMENTAL | - |
| 18 mg LY2189102 | EXPERIMENTAL | - |
| 180 mg LY2189102 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | 0.9% Sodium Chloride |
| Part A LY2189102 0.1 mg/kg/wk | EXPERIMENTAL | Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV) Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 0.3 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 1.0 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV |
| Part A LY2189102 2.5 mg/kg/wk | EXPERIMENTAL | Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV |
| Name | Type | Description |
|---|---|---|
| LY2189102 | DRUG | Participants received 2 subcutaneous (SC) injections weekly for 12 weeks. |
| Placebo | DRUG | Participants received 2 SC injections weekly for 12 weeks. |
Inclusion Criteria: * Have Type 2 Diabetes and confirmed by fasting C-peptide levels greater than or equal to 0.8 nanograms per milliliter \[ng/ml\]), with duration of more than 3 months. * Body mass index between 25 and 40 kilograms per square meter (kg/m2). * Stable on diet and exercise alone, wi...
Top 16 of 30 competitors
LY2189102 is an investigational small molecule being studied for Type 2 Diabetes and Rheumatoid Arthritis. It is developed by Eli Lilly and Company. The drug has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved.
LY2189102 is a small molecule developed by Eli Lilly and Company. Its specific molecular target has not been disclosed in available information. The drug is being studied for its effects in Type 2 Diabetes and Rheumatoid Arthritis, but its mechanism of action is not publicly detailed.
LY2189102 is developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company has sponsored clinical trials evaluating the drug in patients with Type 2 Diabetes and Rheumatoid Arthritis.
LY2189102 is an investigational drug that has completed Phase 1 and Phase 2 clinical trials. It is not approved and remains in clinical development. The most advanced completed trial was a Phase 2 study in Type 2 Diabetes, while a Phase 1 study was conducted in Rheumatoid Arthritis.
LY2189102 has been studied in two completed clinical trials. NCT00380744 was a Phase 1 safety and pharmacokinetics study in participants with Rheumatoid Arthritis, enrolling 121 participants in the United States and Poland. NCT00942188 was a Phase 2 study in patients with Type 2 Diabetes, enrolling 106 participants in the United States.
LY2189102 is not known to have any alternative names. It is an investigational small molecule developed by Eli Lilly and Company, studied under its unique identifier in clinical trials for Type 2 Diabetes and Rheumatoid Arthritis.